mrjСовременная ревматологияModern Rheumatology Journal1996-70122310-158XIMA-PRESS, LLC10.14412/1996-7012-2021-5-108-113mrj-1208Research ArticleОБЗОРЫREVIEWSПрименение ботулинического токсина типа A при ревматических заболеванияхUse of botulinum toxin type A in rheumatic diseaseshttps://orcid.org/0000-0002-4846-5531ЕгороваО. Н.EgorovaO. N.

Ольга Николаевна Егорова

115522, Москва, Каширское шоссе, 34А

Olga Nikolaevna Egorova

34A, Kashirskoe Shosse, Moscow 115522

onegorova@yandex.ruhttps://orcid.org/0000-0001-7091-2054БеловБ. С.BelovB. S.

115522, Москва, Каширское шоссе, 34А

34A, Kashirskoe Shosse, Moscow 115522

https://orcid.org/0000-0001-9797-0182СажинаЕ. Г.SazhinaE. G.

115522, Москва, Каширское шоссе, 34А

34A, Kashirskoe Shosse, Moscow 115522

ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»РоссияV.A. Nasonova Research Institute of RheumatologyRussian Federation202119102021155108113Copyright © Егорова О.Н., Белов Б.С., Сажина Е.Г., 20212021Егорова О.Н., Белов Б.С., Сажина Е.Г.Egorova O.N., Belov B.S., Sazhina E.G.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://mrj.ima-press.net/mrj/article/view/1208

В статье представлен анализ современных данных об эффективности антиноцицептивного действия ботулинического токсина типа А (БТА) при ревматических заболеваниях (РЗ). Обсуждены перспективы использования БТА в терапии боли при разных РЗ. Поиск публикаций проводился в базах данных Medline, Pubmed, Cochrane Library. Как показал анализ данных литературы, БТА может стать дополнительным методом лечения боли при многих РЗ.

The article presents an analysis of modern data on the antinociceptive effectiveness of botulinum toxin type A (BTA) in rheumatic diseases (RD). The prospects for the use of BTA in the treatment of pain in different RDs are discussed. We searched for publications in the Medline, Pubmed, Cochrane Library databases. Analysis of literature data has shown that BTA can become an additional method of pain management in many RDs.

больботулинический токсин типа Аревматические заболеванияpainbotulinum toxin type Arheumatic diseasesРабота выполнена в рамках научной исследовательской работы «Инновационные технологии диагностики и лечения системных заболеваний соединительной ткани» (ИКБРС 0397-2020-0006).The investigation has been conducted within scientific topic №0397-2020-0006 «Innovative technologies for the diagnosis and treatment of systemic connective tissue diseases».ReferencesBreivik H, Collett B, Ventafridda V, et al. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur J Pain. 2006 May;10(4):287-333. doi: 10.1016/j.ejpain.2005.06.009.Epub 2005 Aug 10.Breivik H, Collett B, Ventafridda V, et al. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur J Pain. 2006 May;10(4):287-333. doi: 10.1016/j.ejpain.2005.06.009.Epub 2005 Aug 10.Екушева ЕВ. Коморбидный пациент с хроническим болевым синдромом. Русский медицинский журнал. 2019;(9):44-8.Ekusheva EV. Comorbid patient with chronic pain syndrome. Russkii meditsinskii zhurnal.2019;(9):44-8. (In Russ.).http://www.who.int/nmh/Global_Atlas_of_Palliative_Care.pdfhttp://www.who.int/nmh/Global_Atlas_of_Palliative_Care.pdfНасонова ВА, Каратеев АЕ. Симптоматическая терапия боли при ревматических заболеваниях: место ацеклофенака. Современная ревматология. 2009;3(3):58-65.Nasonova VA, Karateev AE. Symptomatic therapy for pain in rheumatic diseases: a place of aceclofenac. Sovremennaya revmatologiya = Modern Rheumatology Journal.2009;3(3):58-65. (In Russ.). doi: 10.14412/1996-7012-2009-560Zhai S, Huang B, Yu K. The efficacy and safety of Botulinum Toxin Type A in painful knee osteoarthritis: a systematic review and meta-analysis. J Int Med Res. 2019 Dec 29: 300060519895868. doi: 10.1177/0300060519895868.Zhai S, Huang B, Yu K. The efficacy and safety of Botulinum Toxin Type A in painful knee osteoarthritis: a systematic review and meta-analysis. J Int Med Res. 2019 Dec 29: 300060519895868. doi: 10.1177/0300060519895868.Костенко ЕВ, Коновалова ЗН, Орлова ОР, Хатькова СЕ. Ботулотоксин при болевых синдромах. Медицинский совет. 2018;(1):58-63.Kostenko EV, Konovalova ZN, Orlova OR, Khat'kova SE. Botulinum toxin in pain syndromes. Meditsinskii sovet. 2018;(1):58-63. (In Russ.).Aoki KR. Review of a proposed mechanism for the antinociceptive action of botulinumtoxin type A. Neurotoxicology. 2005 Oct;26(5):785-93. doi: 10.1016/j.neuro.2005.01.017. Epub 2005 Jul 5.Aoki KR. Review of a proposed mechanism for the antinociceptive action of botulinumtoxin type A. Neurotoxicology. 2005 Oct;26(5):785-93. doi: 10.1016/j.neuro.2005.01.017. Epub 2005 Jul 5.Goadsby PJ, Edvinsson L. The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol. 1993 Jan;33(1):48-56. doi: 10.1002/ana.410330109.Goadsby PJ, Edvinsson L. The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol. 1993 Jan;33(1):48-56. doi: 10.1002/ana.410330109.Gobel H, Heinze A, Heinze-Kuhn K, Austermann K. Botulinum toxin A in the treatment of headache syndromes and pericranial pain syndromes. Pain. 2001 Apr;91(3): 195-9. doi: 10.1016/S0304-3959(01)00292-5Gobel H, Heinze A, Heinze-Kuhn K, Austermann K. Botulinum toxin A in the treatment of headache syndromes and pericranial pain syndromes. Pain. 2001 Apr;91(3): 195-9. doi: 10.1016/S0304-3959(01)00292-5Silberstein SD. Review of botulinum toxin type A and its clinical applications in migraine headache. Expert Opin Pharmacother. 2001 Oct;2(10):1649-54. doi: 10.1517/14656566.2.10.1649.Silberstein SD. Review of botulinum toxin type A and its clinical applications in migraine headache. Expert Opin Pharmacother. 2001 Oct;2(10):1649-54. doi: 10.1517/14656566.2.10.1649.Aoki KR. Evidence for antinociceptive activity of botulinum toxin type A in pain management. Headache. Jul-Aug 2003;43 Suppl 1: S9-15. doi: 10.1046/j.1526-4610.43.7s.3.x.Aoki KR. Evidence for antinociceptive activity of botulinum toxin type A in pain management. Headache. Jul-Aug 2003;43 Suppl 1: S9-15. doi: 10.1046/j.1526-4610.43.7s.3.x.Gazerani P, Staahl C, Drewes AM, Arendt-Nielsen L. The effects of Botulinum Toxin type A on capsaicin-evoked pain, flare, and secondary hyperalgesia in an experimental human model of trigeminal sensitization. Pain. 2006 Jun;122(3):315-25. doi: 10.1016/j.pain.2006.04.014. Epub 2006 May 4.Gazerani P, Staahl C, Drewes AM, Arendt-Nielsen L. The effects of Botulinum Toxin type A on capsaicin-evoked pain, flare, and secondary hyperalgesia in an experimental human model of trigeminal sensitization. Pain. 2006 Jun;122(3):315-25. doi: 10.1016/j.pain.2006.04.014. Epub 2006 May 4.Gazerani P, Pedersen NS, Staahl C, et al. Subcutaneous Botulinum toxin type A reduces capsaicin-induced trigeminal pain and vasomotor reactions in human skin. Pain. 2009 Jan;141(1-2):60-9. doi: 10.1016/j.pain.2008.10.005. Epub 2008 Nov 11.Gazerani P, Pedersen NS, Staahl C, et al. Subcutaneous Botulinum toxin type A reduces capsaicin-induced trigeminal pain and vasomotor reactions in human skin. Pain. 2009 Jan;141(1-2):60-9. doi: 10.1016/j.pain.2008.10.005. Epub 2008 Nov 11.Артемьев ДВ, Орлова ОР, Моренкова АЭ. Использование ботокса в медицинской практике. Неврологический журнал.2000;5(4):46-51.Artem'ev DV, Orlova OR, Morenkova AE. The use of botox in medical practice. Nevrologicheskii zhurnal.2000;5(4):46-51. (In Russ.).Whitemarsh RC, Tepp WH, Bradshaw M, et al. Characterization of botulinum neurotoxin A subtypes 1 through 5 by investigation of activities in mice, in neuronal cell cultures, and in vitro. Infect Immun. 2013 Oct;81(10): 3894-902. doi: 10.1128/IAI.00536-13. Epub 2013 Aug 5.Whitemarsh RC, Tepp WH, Bradshaw M, et al. Characterization of botulinum neurotoxin A subtypes 1 through 5 by investigation of activities in mice, in neuronal cell cultures, and in vitro. Infect Immun. 2013 Oct;81(10): 3894-902. doi: 10.1128/IAI.00536-13. Epub 2013 Aug 5.Pier CL, Chen C, Tepp WH, et al. Botulinum neurotoxin subtype A2 enters neuronal cells faster than subtype A1. FEBS Lett. 2011 Jan 3;585(1):199-206. doi: 10.1016/j.febslet.2010.11.045. Epub 2010 Nov 30.Pier CL, Chen C, Tepp WH, et al. Botulinum neurotoxin subtype A2 enters neuronal cells faster than subtype A1. FEBS Lett. 2011 Jan 3;585(1):199-206. doi: 10.1016/j.febslet.2010.11.045. Epub 2010 Nov 30.Akaike N, Shin MC, Wakita M, et al. Transsynaptic inhibition of spinal transmission by A2 botulinum toxin. J Physiol. 2013 Feb 15;591(4):1031-43. doi: 10.1113/jphysiol.2012.242131. Epub 2012 Oct 29.Akaike N, Shin MC, Wakita M, et al. Transsynaptic inhibition of spinal transmission by A2 botulinum toxin. J Physiol. 2013 Feb 15;591(4):1031-43. doi: 10.1113/jphysiol.2012.242131. Epub 2012 Oct 29.Mahowald ML, Singh JA, Dykstra D. Long term effects of intra-articular botulinum toxin A for refractory joint pain. Neurotox Res. 2006 Apr;9(2-3):179-88. doi: 10.1007/BF03033937.Mahowald ML, Singh JA, Dykstra D. Long term effects of intra-articular botulinum toxin A for refractory joint pain. Neurotox Res. 2006 Apr;9(2-3):179-88. doi: 10.1007/BF03033937.Singh JA, Mahowald ML. Intra-articular botulinum toxin A as an adjunctive therapy for refractory joint pain in patients with rheumatoid arthritis receiving biologics: a report of two cases. Joint Bone Spine. 2009 Mar;76(2):190-4. doi: 10.1016/j.jbspin.2008.05.006. Epub 2008 Oct 25.Singh JA, Mahowald ML. Intra-articular botulinum toxin A as an adjunctive therapy for refractory joint pain in patients with rheumatoid arthritis receiving biologics: a report of two cases. Joint Bone Spine. 2009 Mar;76(2):190-4. doi: 10.1016/j.jbspin.2008.05.006. Epub 2008 Oct 25.Singh JA, Mahowald ML, Kushnaryov A, et al. Repeat injections of intra-articular botulinum toxin a for the treatment of chronic arthritis joint pain. J Clin Rheumatol. 2009 Feb;15(1):35-8. doi: 10.1097/RHU.0b013e3181953b14.Singh JA, Mahowald ML, Kushnaryov A, et al. Repeat injections of intra-articular botulinum toxin a for the treatment of chronic arthritis joint pain. J Clin Rheumatol. 2009 Feb;15(1):35-8. doi: 10.1097/RHU.0b013e3181953b14.Singh JA, Mahowald ML, Noorbaloochi S. Intra-articular botulinum toxin A for refractory shoulder pain: a randomized, double-blinded, placebo-controlled trial. Transl Res. 2009 May;153(5):205-16. doi: 10.1016 /j.trsl.2009.02.004. Epub 2009 Mar 13.Singh JA, Mahowald ML, Noorbaloochi S. Intra-articular botulinum toxin A for refractory shoulder pain: a randomized, double-blinded, placebo-controlled trial. Transl Res. 2009 May;153(5):205-16. doi: 10.1016 /j.trsl.2009.02.004. Epub 2009 Mar 13.Kidd BL. Osteoarthritis and joint pain. Pain. 2006 Jul;123(1-2):6-9. doi: 10.1016/j.pain.2006.04.009. Epub 2006 May 22.Kidd BL. Osteoarthritis and joint pain. Pain. 2006 Jul;123(1-2):6-9. doi: 10.1016/j.pain.2006.04.009. Epub 2006 May 22.Martell-Pelletier J, Barr AJ, Cicuttini FM, et al. Osteoarthritis. Nat Rev Dis Primers. 2016 Oct 13;2:16072. doi: 10.1038/nrdp.2016.72.Martell-Pelletier J, Barr AJ, Cicuttini FM, et al. Osteoarthritis. Nat Rev Dis Primers. 2016 Oct 13;2:16072. doi: 10.1038/nrdp.2016.72.Ivanusic JJ. Molecular Mechanisms That Contribute to Bone Marrow Pain. Front Neurol. 2017 Sep 11;8:458. doi: 10.3389/fneur.2017.00458. eCollection 2017.Ivanusic JJ. Molecular Mechanisms That Contribute to Bone Marrow Pain. Front Neurol. 2017 Sep 11;8:458. doi: 10.3389/fneur.2017.00458. eCollection 2017.Khenioui H, Houvenagel E, Catanzariti JF, et al. Usefulness of intra-articular botulinum toxin injections. A systematic review. Joint Bone Spine. 2016 Mar;83(2):149-54. doi: 10.1016/j.jbspin.2015.10.001. Epub 2015 Nov 29.Khenioui H, Houvenagel E, Catanzariti JF, et al. Usefulness of intra-articular botulinum toxin injections. A systematic review. Joint Bone Spine. 2016 Mar;83(2):149-54. doi: 10.1016/j.jbspin.2015.10.001. Epub 2015 Nov 29.Schaible HG, Ebersberger A, von Banchet GS. Mechanisms of pain in arthritis. Ann N Y Acad Sci. 2002 Jun;966: 343-54. doi: 10.1111/j.1749-6632.2002.tb04234.x.Schaible HG, Ebersberger A, von Banchet GS. Mechanisms of pain in arthritis. Ann N Y Acad Sci. 2002 Jun;966: 343-54. doi: 10.1111/j.1749-6632.2002.tb04234.x.Hsieh LF, Wu CW, Chou CC, et al. Effects of botulinum toxin landmark-guided intra-articular injection in subjects with knee osteoarthritis. PM R. 2016 Dec;8(12): 1127-35. doi: 10.1016/j.pmrj.2016.05.009. Epub 2016 May 19.Hsieh LF, Wu CW, Chou CC, et al. Effects of botulinum toxin landmark-guided intra-articular injection in subjects with knee osteoarthritis. PM R. 2016 Dec;8(12): 1127-35. doi: 10.1016/j.pmrj.2016.05.009. Epub 2016 May 19.Chou CL, Lee SH, Lu SY, et al. Therapeutic effects of intra-articular botulinum neurotoxin in advanced knee osteoarthritis. J Chin Med Assoc. 2010 Nov; 73(11):573-80. doi: 10.1016/S1726-4901(10)70126-X.Chou CL, Lee SH, Lu SY, et al. Therapeutic effects of intra-articular botulinum neurotoxin in advanced knee osteoarthritis. J Chin Med Assoc. 2010 Nov; 73(11):573-80. doi: 10.1016/S1726-4901(10)70126-X.Cinone N, Letizia S, Santoro L, et al. Intra-articular injection of botulinum toxin type A for shoulder pain in glenohumeral osteoarthritis: a case series summary and review of the literature. J Pain Res. 2018 Jun 25;11:1239-45. doi: 10.2147/JPR.S159700.eCollection 2018.Cinone N, Letizia S, Santoro L, et al. Intra-articular injection of botulinum toxin type A for shoulder pain in glenohumeral osteoarthritis: a case series summary and review of the literature. J Pain Res. 2018 Jun 25;11:1239-45. doi: 10.2147/JPR.S159700.eCollection 2018.Joo YJ, Yoon SJ, Kim CW. A comparison of the short-term effects of a botulinum toxin type a and triamcinolone acetate injection on adhesive capsulitis of the shoulder. Ann Rehabil Med. 2013 Apr;37(2):208-14. doi: 10.5535/arm.2013.37.2.208. Epub 2013 Apr 30.Joo YJ, Yoon SJ, Kim CW. A comparison of the short-term effects of a botulinum toxin type a and triamcinolone acetate injection on adhesive capsulitis of the shoulder. Ann Rehabil Med. 2013 Apr;37(2):208-14. doi: 10.5535/arm.2013.37.2.208. Epub 2013 Apr 30.Sun SF, Hsu CW, Lin HS, et al. Efficacy of intraarticular botulinum toxin A and intraarticular hyaluronate plus rehabilitation exercise in patients with unilateral ankle osteoarthritis: a randomized controlled trial. J Foot Ankle Res. 2014 Feb 6;7(1):9. doi: 10.1186/1757-1146-7-9.Sun SF, Hsu CW, Lin HS, et al. Efficacy of intraarticular botulinum toxin A and intraarticular hyaluronate plus rehabilitation exercise in patients with unilateral ankle osteoarthritis: a randomized controlled trial. J Foot Ankle Res. 2014 Feb 6;7(1):9. doi: 10.1186/1757-1146-7-9.Singh JA, Mahowald ML, Noorbaloochi S. Intraarticular botulinum toxin A for refractory painful total knee arthroplasty: a randomized controlled trial. J Rheumatol. 2010 Nov; 37(11):2377-86. doi: 10.3899/jrheum.100336.Epub 2010 Sep 1.Singh JA, Mahowald ML, Noorbaloochi S. Intraarticular botulinum toxin A for refractory painful total knee arthroplasty: a randomized controlled trial. J Rheumatol. 2010 Nov; 37(11):2377-86. doi: 10.3899/jrheum.100336.Epub 2010 Sep 1.Arendt-Nielsen L, Jiang G, De Gryse R, Turkel C. Intra-articular onabotulinumtoxin A in osteoarthritis knee pain: Effect on human mechanistic pain biomarkers and clinical pain. Scand J Rheumatol. 2017 Jul; 46(4):303-16. doi: 10.1080/03009742.2016.1203988. Epub 2016 Oct 13.Arendt-Nielsen L, Jiang G, De Gryse R, Turkel C. Intra-articular onabotulinumtoxin A in osteoarthritis knee pain: Effect on human mechanistic pain biomarkers and clinical pain. Scand J Rheumatol. 2017 Jul; 46(4):303-16. doi: 10.1080/03009742.2016.1203988. Epub 2016 Oct 13.McAlindon TE, Schmidt U, Bugarin D, et al. Efficacy and safety of single-dose onabotulinumtoxinA in the treatment of symptoms of osteoarthritis of the knee: results of a placebo-controlled, double-blind study. Osteoarthritis Cartilage. 2018 Oct;26(10): 1291-9. doi: 10.1016/j.joca.2018.05.001. Epub 2018 May 9.McAlindon TE, Schmidt U, Bugarin D, et al. Efficacy and safety of single-dose onabotulinumtoxinA in the treatment of symptoms of osteoarthritis of the knee: results of a placebo-controlled, double-blind study. Osteoarthritis Cartilage. 2018 Oct;26(10): 1291-9. doi: 10.1016/j.joca.2018.05.001. Epub 2018 May 9.Плотникова ЕВ, Елькин ВД, Миронов АН и др. Экпериментальное обоснование к использованию в косметической практике нового отечественного иммунобиологического препарата с миорелаксатным действием «релатокс». Биология и экпериментальная медицина. 2011; XXVIII(4):125-30.Plotnikova EV, El'kin VD, Mironov AN, et al. Experimental justification for the use of a new domestic immunobiological drug with a muscle relaxant effect «relatox» in cosmetic practice. Biologiya i ekperimental'naya meditsina. 2011;XXVIII(4):125-30. (In Russ.).Batifol D. Different types of injection in temporomandibular disorders (TMD) treatment. Rev Stomatol Chir Maxillofac Chir Orale. 2016 Sep;117(4):256-8. doi: 10.1016/j.revsto.2016.07.005. Epub 2016 Aug 23.Batifol D. Different types of injection in temporomandibular disorders (TMD) treatment. Rev Stomatol Chir Maxillofac Chir Orale. 2016 Sep;117(4):256-8. doi: 10.1016/j.revsto.2016.07.005. Epub 2016 Aug 23.Sycha T, Graninger M, Auff E, Shinider P. Botulinum toxin in the treatment of Raynaud phenomenon: A pilot study. Eur J Clin Invest. 2004 Apr;34(4):312-3. doi: 10.1111/j.1365-2362.2004.01324.x.Sycha T, Graninger M, Auff E, Shinider P. Botulinum toxin in the treatment of Raynaud phenomenon: A pilot study. Eur J Clin Invest. 2004 Apr;34(4):312-3. doi: 10.1111/j.1365-2362.2004.01324.x.Asad U, Austin B, Tarbox M, Paulger B. Botulinum toxin in the long-term treatment of refractory Raynaud's phenomenon. J Drugs Dermatol. 2019 Sep 1;18(9):943-5.Asad U, Austin B, Tarbox M, Paulger B. Botulinum toxin in the long-term treatment of refractory Raynaud's phenomenon. J Drugs Dermatol. 2019 Sep 1;18(9):943-5.Smith L, Polsky D, Franks AG Jr. Botulinum toxin-A for the treatment of Raynaud syndrome. Arch Dermatol. 2012 Apr; 148(4):426-8. doi: 10.1001/archdermatol.2011.1144.Smith L, Polsky D, Franks AG Jr. Botulinum toxin-A for the treatment of Raynaud syndrome. Arch Dermatol. 2012 Apr; 148(4):426-8. doi: 10.1001/archdermatol.2011.1144.Van Beek AL, Lim PK, Gear AJ, Pritzker MR. Management of vasospastic disorders with botulinum toxin. Plast Reconstr Surg. 2007 Jan;119(1):217-26. doi: 10.1097/01.prs.0000244860.00674.57.Van Beek AL, Lim PK, Gear AJ, Pritzker MR. Management of vasospastic disorders with botulinum toxin. Plast Reconstr Surg. 2007 Jan;119(1):217-26. doi: 10.1097/01.prs.0000244860.00674.57.Neumeister MW. Botulinum toxin type A in the treatment of Raynaud's phenomenon. J Hand Surg Am. 2010 Dec;35(12):2085-92. doi: 10.1016/j.jhsa.2010.09.019.Neumeister MW. Botulinum toxin type A in the treatment of Raynaud's phenomenon. J Hand Surg Am. 2010 Dec;35(12):2085-92. doi: 10.1016/j.jhsa.2010.09.019.Bello RJ, Cooney CM, Melamed E, et al. The therapeutic efficacy of botulinum toxin in treating scleroderma-associated Raynaud's phenomenon: a randomized, double-blind, placebo-controlled clinical trial. Arthritis Rheumatol. 2017 Aug;69(8):1661-9. doi: 10.1002/art.40123. Epub 2017 Jun 26.Bello RJ, Cooney CM, Melamed E, et al. The therapeutic efficacy of botulinum toxin in treating scleroderma-associated Raynaud's phenomenon: a randomized, double-blind, placebo-controlled clinical trial. Arthritis Rheumatol. 2017 Aug;69(8):1661-9. doi: 10.1002/art.40123. Epub 2017 Jun 26.Serri J, Legre R, Veit V, et al. Botulinum toxin type A contribution in the treatment of Raynaud's phenomenon due to systemic sclerosis. Ann Chir Plast Esthet. 2013 Dec;58(6): 658-62. doi: 10.1016/j.anplas.2011.11.001.Epub 2011 Dec 26.Serri J, Legre R, Veit V, et al. Botulinum toxin type A contribution in the treatment of Raynaud's phenomenon due to systemic sclerosis. Ann Chir Plast Esthet. 2013 Dec;58(6): 658-62. doi: 10.1016/j.anplas.2011.11.001.Epub 2011 Dec 26.Motegi S, Yamada K, Toki S, et al. Beneficial effect of botulinum toxin A on Raynaud's phenomenon in Japanese patients with systemic sclerosis: a prospective, case series study. J Dermatol. 2016 Jan;43(1): 56-62. doi: 10.1111/1346-8138.13030. Epub 2015 Jul 15.Motegi S, Yamada K, Toki S, et al. Beneficial effect of botulinum toxin A on Raynaud's phenomenon in Japanese patients with systemic sclerosis: a prospective, case series study. J Dermatol. 2016 Jan;43(1): 56-62. doi: 10.1111/1346-8138.13030. Epub 2015 Jul 15.Medina S, Gomez-Zubiaur A, Valdeolivas-Casillas N, et al. Botulinum toxin type A in the treatment of Raynaud's phenomenon: a three-year follow-up study. Eur J Rheumatol. 2018 Dec;5(4):224-9. doi: 10.5152/eurjrheum.2018.18013. Epub 2018 Oct 12.Medina S, Gomez-Zubiaur A, Valdeolivas-Casillas N, et al. Botulinum toxin type A in the treatment of Raynaud's phenomenon: a three-year follow-up study. Eur J Rheumatol. 2018 Dec;5(4):224-9. doi: 10.5152/eurjrheum.2018.18013. Epub 2018 Oct 12.Herrick AL. The pathogenesis, diagnosis and treatment of Raynaud phenomenon. Nat Rev Rheumatol. 2012 Aug;8(8):469-79. doi: 10.1038/nrrheum.2012.96. Epub 2012 Jul 10.Herrick AL. The pathogenesis, diagnosis and treatment of Raynaud phenomenon. Nat Rev Rheumatol. 2012 Aug;8(8):469-79. doi: 10.1038/nrrheum.2012.96. Epub 2012 Jul 10.Wigley FM. Clinical practice Raynaud's phenomenon. N Engl J Med. 2002 Sep 26; 347(13):1001-8. doi: 10.1056/NEJMcp013013.Wigley FM. Clinical practice Raynaud's phenomenon. N Engl J Med. 2002 Sep 26; 347(13):1001-8. doi: 10.1056/NEJMcp013013.Cui M, Khanijou S, Rubino J, Aoki KR. Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain. 2004 Jan;107(1-2):125-33. doi: 10.1016/j.pain.2003.10.008.Cui M, Khanijou S, Rubino J, Aoki KR. Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain. 2004 Jan;107(1-2):125-33. doi: 10.1016/j.pain.2003.10.008.Stone AV, Koman AL, Callahan MF, et al. The effect of botulinum neurotoxin-A on blood flow in rats: a potencial mechanism for treatment of Raynaud phenomenon. J Hand Surg Am. 2012 Apr;37(4):795-802. doi: 10.1016/j.jhsa.2012.01.021. Epub 2012 Mar 3.Stone AV, Koman AL, Callahan MF, et al. The effect of botulinum neurotoxin-A on blood flow in rats: a potencial mechanism for treatment of Raynaud phenomenon. J Hand Surg Am. 2012 Apr;37(4):795-802. doi: 10.1016/j.jhsa.2012.01.021. Epub 2012 Mar 3.Setler P. Therapeutic use of botulinum toxins: back-ground and history. Clin J Pain. Nov-Dec 2002;18(6 Suppl):S119-24. doi: 10.1097/00002508-200211001-00002.Setler P. Therapeutic use of botulinum toxins: back-ground and history. Clin J Pain. Nov-Dec 2002;18(6 Suppl):S119-24. doi: 10.1097/00002508-200211001-00002.O'Neil LM, Palme CE, Riffat F, Mahant N. Botulinum toxin for the management of Sjö gren syndrome-associated recurrent parotitis. J Oral Maxillofac Surg. 2016 Dec; 74(12):2428-30. doi: 10.1016/j.joms.2016.06.169. Epub 2016 Jun 18.O'Neil LM, Palme CE, Riffat F, Mahant N. Botulinum toxin for the management of Sjö gren syndrome-associated recurrent parotitis. J Oral Maxillofac Surg. 2016 Dec; 74(12):2428-30. doi: 10.1016/j.joms.2016.06.169. Epub 2016 Jun 18.Daniel SJ, Diamond M. Botulinum toxin injection: a novel treatment for recurrent cystic parotitis Sjö gren syndrome. Otolaryngol Head Neck Surg. 2011 Jul;145(1):180-1. doi: 10.1177/0194599811398596.Daniel SJ, Diamond M. Botulinum toxin injection: a novel treatment for recurrent cystic parotitis Sjö gren syndrome. Otolaryngol Head Neck Surg. 2011 Jul;145(1):180-1. doi: 10.1177/0194599811398596.Spiera H, Asbell PA, Simpson DM. Botulinum toxin increases tearing in patients with Sjö gren's syndrome: a preliminary report. J Rheumatol. 1997 Sep;24(9):1842-3.Spiera H, Asbell PA, Simpson DM. Botulinum toxin increases tearing in patients with Sjö gren's syndrome: a preliminary report. J Rheumatol. 1997 Sep;24(9):1842-3.Francis IC, Coroneo MT. Botulinum toxin increases tearing in patients with Sjö gren's syndrome: a preliminary report. J Rheumatol. 1998 Sep;25(9):1859.Francis IC, Coroneo MT. Botulinum toxin increases tearing in patients with Sjö gren's syndrome: a preliminary report. J Rheumatol. 1998 Sep;25(9):1859.

The authors declare that there are no conflicts of interest present.